Back to Search
Start Over
Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
- Source :
-
Neurologia medico-chirurgica [Neurol Med Chir (Tokyo)] 2011; Vol. 51 (4), pp. 319-25. - Publication Year :
- 2011
-
Abstract
- Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM. Here, we describe 3 cases of GBM patients treated with autologous formalin-fixed tumor vaccine (AFTV) combined with TMZ. All cases demonstrated pathological changes associated with the therapy. After a 4-week break from the standard initial treatments, 1 patient with primary GBM and 2 patients with secondary GBM received adjuvant TMZ for 5 days combined with AFTV injection and were subsequently treated with multiple cycles of adjuvant TMZ for 5 days every 28 days (AFTV/TMZ therapy). Adverse effects related to AFTV plus TMZ were very minor in all patients. Magnetic resonance imaging revealed partial response in 2 patients. CD3(+)CD8(+) lymphocytes were frequently detected in surgical specimens and MIB-1 labeling index in 2 cases decreased after AFTV/TMZ therapy. AFTV/TMZ therapy is suitable for larger scale clinical trials.
- Subjects :
- Adjuvants, Immunologic therapeutic use
Adult
Aged
Brain Neoplasms immunology
Brain Neoplasms pathology
Combined Modality Therapy
Dacarbazine therapeutic use
Female
Formaldehyde
Frontal Lobe pathology
Glioblastoma immunology
Glioblastoma pathology
Humans
Male
Middle Aged
Temozolomide
Treatment Outcome
Antineoplastic Agents, Alkylating therapeutic use
Brain Neoplasms therapy
Cancer Vaccines therapeutic use
Dacarbazine analogs & derivatives
Glioblastoma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1349-8029
- Volume :
- 51
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Neurologia medico-chirurgica
- Publication Type :
- Academic Journal
- Accession number :
- 21515959
- Full Text :
- https://doi.org/10.2176/nmc.51.319